Patents by Inventor Dieter Rudnick
Dieter Rudnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780909Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: February 5, 2021Date of Patent: October 10, 2023Assignee: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Publication number: 20220227841Abstract: A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content.Type: ApplicationFiled: April 8, 2022Publication date: July 21, 2022Inventors: Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
-
Patent number: 11325964Abstract: A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content.Type: GrantFiled: July 26, 2017Date of Patent: May 10, 2022Assignee: BIOTEST AGInventors: Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
-
Publication number: 20210179694Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: February 5, 2021Publication date: June 17, 2021Applicant: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 10954290Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: July 9, 2018Date of Patent: March 23, 2021Assignee: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Publication number: 20190161533Abstract: A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content.Type: ApplicationFiled: July 26, 2017Publication date: May 30, 2019Inventors: Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
-
Publication number: 20180319871Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: July 9, 2018Publication date: November 8, 2018Applicant: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 10059759Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5 % IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: November 10, 2016Date of Patent: August 28, 2018Assignee: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Publication number: 20170058020Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Applicant: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 9518110Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: October 31, 2014Date of Patent: December 13, 2016Assignee: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 9243056Abstract: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.Type: GrantFiled: October 19, 2012Date of Patent: January 26, 2016Assignee: BIOTEST AGInventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Herbert Dichtelmueller, Eckhard Flechsig
-
Publication number: 20150064170Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: October 31, 2014Publication date: March 5, 2015Applicant: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 8900806Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: October 19, 2012Date of Patent: December 2, 2014Assignee: Biotest AGInventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 7041798Abstract: The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium sulfate buffer. The invention also relates to preparations obtained by using said method and to their use.Type: GrantFiled: June 23, 2000Date of Patent: May 9, 2006Assignee: Biotest Pharma GmbHInventors: Norbert Kothe, Dieter Rudnick, Michael Kloft
-
Patent number: 5190752Abstract: An intravenously administrable polyclonal immunoglobulin preparation for the treatment and prophylaxis of bacterial infections containing at least 50% by weight of IgM in terms of the total content of immunoglobulin, exhibiting a low anticomplementary activity, being stable in aqueous solution, and being free of viruses. It can also consist of or also contain a mixture of several monoclonal IgM antibodies. The source material for its manufacture is an immunoglobulin-containing fraction of human, animal, or bacterial provenance. The fraction is treated with an anion exchanger that is eluted with a saline or pH gradient and the eluate is optionally subjected to gel filtration, treated before or after the chromatography with .beta.-propiolactone and PEG 4000, and optionally heated. Treatment with .beta.-propiolactone and ultraviolet light, treatment with solvents and detergents, or pasteurization can also be conducted. Proteins, sugars, or mixtures of amino acids are optionally added to the preparation.Type: GrantFiled: July 14, 1989Date of Patent: March 2, 1993Assignee: Biotest Pharma GmbHInventors: Wolfgang Moller, Hebert Dichtelmuller, Norbert Kothe, Dieter Rudnick, Detlef Piechaczek
-
Patent number: 5164487Abstract: Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.Type: GrantFiled: March 15, 1991Date of Patent: November 17, 1992Assignee: Biotest Pharma GmbHInventors: Norbert Kothe, Dieter Rudnick, Detlef Piechaczek, Herwald Klein, Detlef Rohm, Michael Kloft
-
Patent number: 5075425Abstract: Process for the preparation of an immunoglobulin solution suitable for intravenous administration from a human blood protein fraction containing immunoglobulins IgG, IgA and IgM in partially concentrated from, with the process steps: addition of acetate buffer to the protein fraction, where appropriate removal of insoluble constituents by filtration, treatment with calcium phosphate and octanoic acid, centrifugation, removal of the supernatant and treatment thereof with an adsorbent, removal of the adsorbent and sterilization by filtration.Type: GrantFiled: August 1, 1990Date of Patent: December 24, 1991Assignee: Biotest Pharma GmbHInventors: Ronald Kotitschke, Wolfgang Stephan, Wolfgang Moller, Detlef Piechaczek, Dieter Rudnick
-
Patent number: 5041537Abstract: To provide a simple method of preparing biologically active transferrin that can be employed on an industrial scale and that will result in extremely pure and natural transferrin containing no viruses and appropriate for both in-vitro and in-vivo applications, the .gamma.-globulins are precipitated from the fraction containing the transferrin, the precipitant is removed from the residual liquid by ultrafiltration or gel filtration, the liquid is adjusted to a prescribed ionic concentration and protein concentration and (a) treated with .beta.-propiolactone and the solution is subjected to ultraviolet radiation or (b) treated with specific detergents and subjected to ion-exchange chromatography, and the transferrin is concentrated and filtered sterile.Type: GrantFiled: September 27, 1988Date of Patent: August 20, 1991Assignee: Biotest Pharma GmbHInventors: Ulf Bethke, Norbert Kothe, Dieter Rudnick, Wolfgang Moller, Michael Kloft
-
Patent number: 4877866Abstract: A method of producing a virus-safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation. The object is to make the method appropriate for industrial-scale production and economical by means of the enrichment and multistage purification of a plasma that has had the coagulation factors removed from it or of a plasma fraction or serum fraction that contains immunoglobulin G accompanied by treatment with ion exchangers and by ultrafiltration. The precipitant is eliminated, by means of diafiltration or gelfiltration, either from the plasma that has had the coagulation factors removed from it or from the plasma fraction that contains the immunoglobulin G, and the desired ion composition is established. The resulting protein solution is subjected to fractionation over an ion exchanger to separate the immunoglobulin G.Type: GrantFiled: November 18, 1987Date of Patent: October 31, 1989Assignee: Biotest Pharma GmbHInventors: Dieter Rudnick, Norbert Kothe, Herbert Dichtelmuller, Detlef Piechaczek, Wolfgang Stephan, Hans Schleussner